Bioinvent Reports Positive Phase 1 Results for BI-1808 in Solid Tumors
What happened
Bioinvent released new study results in the American Association for Cancer Research journal. The Phase 1 trial, involving 24 patients with advanced solid tumors, showed that BI-1808 monotherapy had an excellent safety profile and no dose-limiting toxicities. Results included durable partial response in a GIST patient and a complete response in an ovarian cancer patient.
From finanznachrichten.de
Why it matters
The study findings support BI-1808's mechanism of action, which involves T cell activation and regulatory T cell depletion. Positive clinical trial results in oncology are critical for advancing drug candidates toward commercialization and regulatory approval.
From finanznachrichten.de
Who's involved
- BioinventCompany that conducted the clinical trial and published the study results.
- American Association for Cancer ResearchScientific society where Bioinvent published the study results.
- Merck KGaAGerman multinational company actively competing with Bioinvent in drug development.
Keep exploring
The entities involved
-
Bioinvent
Swedish clinical-stage biotech company
-
American Association for Cancer Research
scientific society
Nothing else this week.